| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Vorsetuzumab (anti-CD70)
CAS:1165740-62-4
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:5mg Remarks:K10823
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
17754423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Vorsetuzumab
CAS:1165740-62-4
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Vorsetuzumab
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:Vorsetuzumab
CAS:1165740-62-4
Purity:99.29% (SEC-HPLC) Package:1mg/RMB 2320;5mg/RMB 5490;10mg/RMB 7480
|
|
| | Vorsetuzumab Basic information |
| Product Name: | Vorsetuzumab | | Synonyms: | Vorsetuzumab;Research Grade Vorsetuzumab(DHE01902);Vorsetuzumab (anti-CD70);SGN-70;Research Grade Vorsetuzumab | | CAS: | 1165740-62-4 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Vorsetuzumab Structure]() |
| | Vorsetuzumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Vorsetuzumab Usage And Synthesis |
| Uses | Vorsetuzumab (Anti-Human CD70 Recombinant Antibody) is a human anti-CD70 antibody. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells, shows inhibitory efficacy against Burkitt’s lymphoma[1]. | | in vivo | Vorsetuzumab (10 mg/kg; i.p.; every other day; for 12 d) inhibits Burkitt’s lymphoma cell growth growth in SRG mice[1].
| Animal Model: | Burkitt’s lymphoma xenograft model in SRG mice[1] | | Dosage: | 10 mg/kg | | Administration: | Intraperitoneal injection; every other day; for 12 d | | Result: | Effectively inhibited Burkitt’s lymphoma cell growth but was not outperform the combination of the KWAR23 antibody (10 mg/kg). |
| | References | [1] Ring NG, et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585. DOI:10.1073/pnas.1710877114 |
| | Vorsetuzumab Preparation Products And Raw materials |
|